All In Biotech

Drug Trial Radar · NCT02315066

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS

Last checked: Nov 19, 2026Latest source record: Apr 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

174

Actual

Start

Apr 23, 2015

Primary completion

Nov 12, 2020

Study completion Nov 12, 2020

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 11, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Conditions

  • Neoplasms

Interventions

  • PF-04518600Drug

    Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined

  • PF-04518600Drug

    Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously

  • PF-04518600 plus PF-05082566Drug

    Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.

  • PF-04518600 plus PF-05082566Drug

    Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicities (DLTs) in Part A1Time frame: The first 2 cycles of treatment (Day 1 up to Day 28)
  2. Number of Participants With All-Causality Treatment Emergent Adverse Events(TEAEs) and Serious Adverse Event(SAEs), Treatment-Related TEAEs and SAEs in Part ATime frame: AEs: The informed consent date up to the last dosing date + 28 days or all drug-related toxicities resolved date. SAEs: The informed consent date through first dosing date + 98 days or up to the last dosing date + 60 days, and any post-reporting period.
  3. Number of Participants With Laboratory Test Abnormalities in Part ATime frame: The first dosing date to the earlier date between the last dosing date + 35 days and the first new anti-cancer therapy date (if applicable)
  4. Number of Participants With DLTs in Part B1Time frame: The First 2 Cycles of Treatment (Day 1 up to Day 28)
  5. Number of Participants With All-causality TEAEs and SAEs, and Treatment-Related TEAEs and SAEs in Part BTime frame: AEs: The informed consent date up to the last dosing date + 60 days or all drug-related toxicities resolved date. SAEs: The informed consent date through first dosing date + 98 days or up to the last dosing date + 60 days, and any post-reporting period.
  6. Number of Participants With Laboratory Test Abnormalities in Part BTime frame: The first dosing date to the earlier date between the last dosing date + 35 days and the first new anti-cancer therapy date (if applicable)

Locations

30 sites in 4 countries. Site status is shown where the registry gives one.

  • The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate

    Los Angeles, California

  • Keck Hospital of USC

    Los Angeles, California

  • LAC+USC Medical Center

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • Ronald Regan Medical Center

    Los Angeles, California

  • UCLA Hematology & Oncology Clinic

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Medical Imaging Center of Southern California, Inc.

    Santa Monica, California

  • Santa Monica UCLA Hematology & Oncology Clinic

    Santa Monica, California

  • UConn Health, Pharmacy

    Farmington, Connecticut

  • UConn Health, Neag Comprehensive Cancer Center

    Farmington, Connecticut

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida

  • Massachusetts General Hospital (MGH)

    Boston, Massachusetts

  • Brigham & Women's Hospital (BWH)

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center (BIDMC)

    Boston, Massachusetts

  • Dana-Farber Cancer Institute (DFCI)

    Boston, Massachusetts

  • Massachusetts General/Chelsea HealthCare Center

    Chelsea, Massachusetts

  • Mass General/North Shore Center for Outpatient Care

    Danvers, Massachusetts

  • Mass General West

    Waltham, Massachusetts

  • Columbia University Medical Center - Herbert Irving Pavilion

    New York, New York

  • Methodist Hospital-Pathology

    Houston, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • University of Washington Medical Center

    Seattle, Washington

  • Groupe hospitalier Pitie Salpetriere

    Paris, France

  • Institut Gustave Roussy

    Villejuif, France

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan

  • The Netherlands Cancer Institute

    Amsterdam, Netherlands

  • Slotervaart Hospital/Antoni van Leeuwenhoek

    Amsterdam, Netherlands

  • Erasmus MC

    Rotterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.